BioInformant

Your Global Leader in Stem Cell Market Research

Home » Exosomes » Page 12

Global Cooperation – MD Anderson and NIH to Fund Clinical Trial Combining Mesoblast Technologies

By

MD Anderson Cancer Center and National Institutes of Health to Fund Trial Combining 2 Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients


New York, USA; and Melbourne, Australia; December 6, 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that MD Anderson Cancer Center (MDACC) in Texas and the United States National Institutes of Health (NIH) will fund a clinical trial combining Mesoblast’s two synergistic proprietary technologies, Mesenchymal Precursor Cell (MPC)-based expansion and ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplMesoblastantation in cancer patients. The trial will provide clinical data on whether the combination of these two technologies synergistically facilitates more rapid cord blood HSC engraftment for bone marrow transplant patients than can be achieved by either technology alone.

The number of allogeneic bone marrow transplants performed globally each year could be substantially increased beyond the current 30,000, for cancer and non-cancer indications, if safe and effective alternative sources of allogeneic HSCs are available, such as cord blood, for patients who cannot find a matched donor. Unfortunately, cord blood transplants are associated with prolonged engraftment times due to insufficient numbers and inadequate homing capacity of cord blood HSCs, adversely impacting their clinical outcomes. [Read more…]

This Week in Stem Cells – MSCs, Exosomes, Sertoli Cells, and More

By

It was a interesting week in the stem cell sector, with new releases about MSCs, exosomes, Sertoli cells, and more. Check out this coverage of the stem cell industry and let me know what you think?

Breaking News! Altucell Releases Evidence in Support of Microencapsulated Sertoli Cells for Reversal of Diabetes 

According to the Center for Disease Control (CDC), 29.1 million people or 9.3% of the U.S. population has diabetes, including an estimated 8.1 million who are undiagnosed. One small but powerful company working in this area is AltuCell, a company whose mission is to find a cure to diabetes. In a recent peer-review article published in the journal Xenotransplantation (September 2016), AltuCell’s medical lead Dr. Giovanni Luca reported a preclinical breakthrough utilizing microencapsulated Sertoli cells to establish reversal of diabetes in a mouse model. An important voice in support of the recent findings was Dr. David White of the Schulich School of Medicine who released an article about the breakthrough titled, “A Cure for Type 2 Diabetes?”

What are Exosomes? The Exosome Revolution is Here

What are exosomes? This is an important question, because exosomes have recently exploded in popularity. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. Ten years ago in 2006, there were only 76 articles published about exosomes. Today, there are more than 4,400 articles published about exosomes, of which 1,088 (~25%) were released in the 2016 calendar year. Clearly, there has been an explosion of interest in exosomes, making it important for the scientific community to understand the functionality and importance of these nano-sized vesicles.   [Read more…]

Role of MSC-Derived Exosomes in Healing the Injured Spinal Cord – Interview with Dr. Askenase

By

MSC Exosomes, Dr. Askenase
Dr. Philip Askenase, Professor at Yale University School of Medicine

This is an interview with Philip Askenase, MD, Professor of Medicine and Pathology at Yale University School of Medicine. Dr. Askenase is an expert in the effector  properties of exosomes who is now beginning to study mesenchymal stem cell (MSC)-derived exosomes and their role in regenerative processes.

Specifically, Dr. Askenase’s new unpublished preliminary work is focused on the role of MSC-derived exosomes in healing the injured spinal cord in rats.

In this interview, we discuss the growing importance of MSC-derived exosomes, including their advantages and applications. We also explore the market potential for stem cell exosomes, as well as companies competing in this emerging market area.

[Read more…]

BioInformant's World-Class Clients